NEW YORK (Reuters) -Large deals involving pharmaceutical and biotech companies are stalling as executives grapple with ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Merck (NYSE:MRK) stock in focus as the company partners with Jiangsu Hengrui in a $2B deal for heart disease therapy HRS-5346 ...

Shares of Merck & Co. Inc. slipped 4.81% to $87.87 Tuesday, on what proved to be an all-around favorable trading session for ...

Pressure may grow on companies to repatriate production, raising production costs and potentially medicine prices too.

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

The Mayo Clinic and Exact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

We recently published a list of 12 Best Consistent Dividend Stocks to Buy. In this article, we are going to take a look at ...

We recently published a list of Jim Cramer Recently Put These 10 Stocks Under Spotlight. In this article, we are going to ...